Description

JMJD3/HDAC-IN-1 (compound A5b) is a dual inhibitor targeting Jumonji domain-containing protein demethylase 3 (JMJD3) and histone deacetylase (HADC1, IC50=16 nM). JMJD3/HDAC-IN-1 promotes hypermethylation of histone H3K27 and hyperacetylation of H3K9, and also cleaves caspase-7 and PARP to induce apoptosis. JMJD3/HDAC-IN-1 effectively inhibits cancer cell cloning, migration, and invasion[1].–Applications–Formula-C21H30N6O2-Citation–References-[1]Li A, et al. Design, synthesis and biological evaluation of pyrimidine base hydroxamic acid derivatives as dual JMJD3 and HDAC inhibitors. Bioorg Med Chem Lett. 2023 Oct 1;94:129466.. .-CASNumber-2883046-06-6-MolecularWeight-398.50-Compound Purity–SMILES-O=C(CCCCCNC1=NC(C2=NC=CC=C2)=NC(N3CCCCCC3)=C1)NO-Research_Area-cancer-Solubility-10 mM in DMSO-Target-Apoptosis;HDAC;Histone Demethylase-Isoform–Pathway-Apoptosis;Cell Cycle/DNA Damage;Epigenetics-MCE Product type-ADC Related